HIT ANTI-PF4 TEST KITS – Evidence Summary
RT-PCR CYCLE THRESHOLD VALUES – Evidence Summary
HIGH FLOW NASAL CANNULA – Evidence Summary
HEMOPERFUSION – Evidence Summary
MOLNUPIRAVIR – Evidence Summary
RAPID ANTIGEN TEST – Evidence Summary
BBIBP-CorV (SINOPHARM) – Evidence Summary
CONVALESCENT PLASMA – Evidence Summary
Dr. Jemelyn Garcia, FPCP, FPSMID
Dr. Maria Sonia Salamat, FPCP, FPSMID
Dr. Marja B. Buensalido, FPCP, FPSMID
Dr. Emmerson Gale Vista, FPDS
Dr. Clarisse Garcia-Mendoza, FPDS
Dr. Kingbherly L. Li, FPCP, FPSMID
Dr. Yvette Silubrico, FPCP, FPSMID
Dr. Chatie Olasiman, FPCP, FPSMID
Dr. Ma. Charmian Hufano, FPCP, FPSMID
Dr. Mitzie Lou Osabel, FPCP, FPSMID
Dr. Janice C. Caoili, FPCP, FPSMID
The Philippine Society for Microbiology and Infectious Diseases (PSMID) Guidance on the Management of Mpox, Ver. 1 provides the basic and most updated information on management of patients confirmed with mpox.
This guidance complements the mpox recommendations of the DOH (Updated Interim Guidelines on the Prevention, Detection, and Management of MPOX, by Department of Health, August 26, 2024, Department Memorandum 2024-0306) and PHICS-PHICNA (Interim Guidelines on the Prevention and Control of Monkeypox version 1).
The antivirals, immunoglobulin and vaccines discussed below are not available locally. In our local situation, we should maximize supportive care for mpox cases.